Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

Schroeder, Eric

366 - Poster Session B
Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

Sunday, March 23, 2014: 3:00 PM

West Exhibit Hall (Tampa Convention Center)

E. D. Schroeder¹, X. Burbano-Levy², J. De La Garza¹, A. E. Garcia-Soto³, K. E. Hew¹, F. Andrade¹, F. Simpkins⁴, J. M. Pearson⁵, J. A. Lucci III⁶ and J. P. Diaz⁷
¹University of Miami-Jackson Memorial Hospital, Miami, FL, ²Zilonis Health, Inc., Miami, FL, ³University of Miami Jackson Memorial Hospital, Miami, FL, ⁴University of Miami, Miami, FL, ⁵University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, ⁶University of Miami Miller School of Medicine, Miami, FL, ⁷South Miami Gynecologic Oncology Group, Miami, FL

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

366 - Poster Session B
Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

366 - Poster Session B Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

366 - Poster Session B
Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis